PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.48%
Negative revenue growth while 3088.T stands at 8.07%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.46%
Negative gross profit growth while 3088.T is at 11.28%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.95%
Negative EBIT growth while 3088.T is at 60.41%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-28.32%
Negative operating income growth while 3088.T is at 58.44%. Joel Greenblatt would press for urgent turnaround measures.
-25.47%
Negative net income growth while 3088.T stands at 51.01%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-25.47%
Negative EPS growth while 3088.T is at 53.44%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-25.47%
Negative diluted EPS growth while 3088.T is at 53.53%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.07%
10Y revenue/share CAGR above 1.5x 3088.T's 30.39%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
64.73%
5Y revenue/share CAGR above 1.5x 3088.T's 6.29%. David Dodd would look for consistent product or market expansions fueling outperformance.
32.48%
3Y revenue/share CAGR above 1.5x 3088.T's 2.16%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.36%
Net income/share CAGR at 75-90% of 3088.T's 145.51%. Bill Ackman would press for strategic moves to boost long-term earnings.
101.74%
5Y net income/share CAGR above 1.5x 3088.T's 63.86%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
77.60%
3Y net income/share CAGR above 1.5x 3088.T's 18.79%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
195.62%
10Y equity/share CAGR 1.25-1.5x 3088.T's 132.01%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
123.30%
5Y equity/share CAGR above 1.5x 3088.T's 46.72%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
57.64%
3Y equity/share CAGR above 1.5x 3088.T's 24.03%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
266.67%
5Y dividend/share CAGR above 1.5x 3088.T's 75.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
144.44%
3Y dividend/share CAGR above 1.5x 3088.T's 40.00%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-3.70%
Firm’s AR is declining while 3088.T shows 9.34%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
5.46%
Inventory growth well above 3088.T's 2.49%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-0.01%
Negative asset growth while 3088.T invests at 5.44%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.68%
Similar to 3088.T's 3.62%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-5.56%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
0.60%
SG&A declining or stable vs. 3088.T's 5.60%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.